COMPOUND DEEP DIVES
PT-141 Bremelanotide melanocortin research has attracted significant scientific attention owing to this cyclic heptapeptide’s distinctive receptor binding profile across the central melanocortin system. Derived from a metabolite of Melanotan-2, PT-141 (Bremelanotide) lacks the peripheral vascular activity associated with its parent compound yet retains potent affinity for MC3R and MC4R subtypes — a selectivity pattern that makes it a valuable research tool in preclinical investigations of hypothalamic neuropeptide circuits. Our team of specialist researchers has compiled this authenticated overview of PT-141’s pharmacological profile, mechanistic research findings, and behavioural assay methodologies as observed in rodent models.
PT-141 (Bremelanotide; CAS 189691-06-3) is a cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). Structurally, it is formed through cyclisation of Melanotan-2 following hydrolysis of the C-terminal amide, yielding a compound with a distinct receptor engagement pattern relative to both the endogenous ligand and its immediate synthetic predecessor.
The five established melanocortin receptor subtypes (MC1R–MC5R) are differentially expressed across peripheral and central tissues. Alpha-MSH binds all five subtypes with moderate to high affinity; Melanotan-2 displays strong activity at MC1R in addition to central subtypes. Verified preclinical binding studies, however, characterise PT-141 as markedly less active at MC1R compared with Melanotan-2, conferring a relative CNS-directed selectivity that researchers have leveraged to isolate central melanocortin system effects from peripheral pigmentation responses.
The table below summarises receptor binding affinity data (reported as approximate Ki values in published in vitro radioligand displacement assays) across the three most studied melanocortin ligands. Data collated from peer-reviewed preclinical literature; values represent representative ranges rather than absolute constants, as assay conditions vary across laboratories.
| Compound | MC1R (Ki, nM) | MC3R (Ki, nM) | MC4R (Ki, nM) | MC5R (Ki, nM) | CNS Selectivity Notes |
|---|---|---|---|---|---|
| alpha-MSH | 0.9–2.5 | 3.0–6.5 | 1.5–4.0 | 2.0–5.5 | Non-selective; endogenous ligand for all subtypes |
| Melanotan-2 | 0.3–1.0 | 1.5–4.0 | 0.5–2.0 | 1.0–3.5 | High MC1R activity; strong peripheral pigmentation signal in animal models |
| PT-141 (Bremelanotide) | 28–70 | 2.0–5.5 | 0.7–2.5 | 3.0–8.0 | Markedly reduced MC1R engagement; preferential MC3R/MC4R profile in preclinical assays |
This differential binding profile has been extensively cited in preclinical literature as a rationale for using PT-141 as a research tool to interrogate central melanocortin circuitry independently of the MC1R-mediated pathway. For a deeper comparison of Melanotan-2’s receptor selectivity and its own CNS research applications, researchers may consult our expert overview at Melanotan-2 CNS Neuroprotective Melanocortin Research.
MC4R is expressed at high density within the hypothalamus — particularly in the paraventricular nucleus (PVN), arcuate nucleus, and dorsomedial hypothalamic nucleus — as well as in limbic structures including the medial amygdala. Researchers have used immunohistochemical mapping and in situ hybridisation across rodent and non-human primate brain atlases to characterise this expression landscape, providing the anatomical foundation for understanding the downstream consequences of MC4R activation by PT-141 Bremelanotide in preclinical models.
MC4R is a Gs-coupled receptor; agonist engagement initiates a canonical cAMP/PKA signalling cascade. In verified hypothalamic slice preparations and rodent in vivo microdialysis studies, researchers have observed that administration of MC4R-selective agonists — including PT-141 — is associated with downstream modulation of cAMP accumulation in PVN neurons. Expert electrophysiological investigations in rodent models have further documented changes in the firing patterns of hypothalamic neurones following MC4R engagement, with particular attention to oxytocin-positive PVN neurones, which co-express MC4R at documented levels.
An additional mechanistic dimension explored in preclinical research involves PT-141 Bremelanotide’s interaction with MC3R, which is expressed in arcuate nucleus NPY/AgRP neurones and may function as an autoreceptor modulating melanocortin tone. Research suggests that the MC3R component of PT-141’s binding profile may contribute to circuit-level effects that are distinct from pure MC4R agonism, a nuance that specialist investigators have highlighted as warranting further dissection in future preclinical work.
Preclinical behavioural research involving PT-141 Bremelanotide melanocortin compounds has employed standardised assay batteries adapted for rodent models. Our team’s authenticated review of this literature identifies several commonly reported methodological approaches:
These methodological frameworks are consistent with those applied in Melanotan-2 preclinical CNS investigations. Researchers interested in parallel melanocortin circuit methodologies may also review the pigmentation receptor research outlined at Melanotan-2 Melanocortin Receptor Pigmentation Research, which contextualises the MC1R-driven peripheral pathway that PT-141 largely bypasses.
For in vitro and in vivo preclinical research applications, the physicochemical stability and authenticated purity of PT-141 Bremelanotide preparations are critical variables. The cyclic structure of PT-141 confers improved proteolytic stability relative to linear alpha-MSH analogues, with verified HPLC purity data from specialist synthesis facilities typically exceeding 98% for research-grade preparations.
Reconstitution for laboratory use conventionally employs bacteriostatic water or sterile saline at pH-adjusted conditions, with researchers advised to follow validated lyophilised peptide handling protocols to preserve biological activity. Aliquoted storage under inert atmosphere at −80 °C is the documented standard for long-term stability in research settings, with stability data from authenticated peptide characterisation studies supporting activity maintenance over multi-month storage periods under these conditions.
If your laboratory requires verified, research-grade PT-141 Bremelanotide for preclinical melanocortin receptor studies, our specialist-curated supply is available for authenticated research purposes: View PT-141 Bremelanotide — Research Grade.
PT-141 (Bremelanotide) is a cyclic heptapeptide derived from Melanotan-2 through hydrolysis of its C-terminal amide group. This structural modification eliminates the majority of MC1R binding affinity present in Melanotan-2, yielding a compound with preferential MC3R/MC4R engagement in preclinical binding assays. Researchers have characterised this distinction as pharmacologically significant because it allows investigation of central melanocortin circuit activity with substantially reduced peripheral pigmentation-pathway confounds in animal models.
In vitro radioligand displacement studies and preclinical animal model investigations indicate that PT-141 Bremelanotide displays highest affinity at MC4R and MC3R, with markedly reduced activity at MC1R relative to alpha-MSH or Melanotan-2. Research suggests that MC4R engagement — particularly at hypothalamic sites including the paraventricular nucleus — is the primary mechanistic driver of the central effects researchers have observed in rodent models following PT-141 administration.
MC4R is a Gs protein-coupled receptor; agonist engagement by PT-141 Bremelanotide initiates adenylyl cyclase activation and subsequent elevation of intracellular cyclic AMP (cAMP) levels. Downstream PKA activation has been documented in hypothalamic neurone preparations in preclinical research. Researchers have also observed changes in CREB phosphorylation and immediate early gene expression (including c-Fos) in relevant hypothalamic nuclei following MC4R agonism in rodent models.
MC4R-null (knockout) mouse lines have been an authenticated tool for verifying the receptor specificity of observed PT-141 Bremelanotide effects. When researchers administer PT-141 to MC4R KO animals, preclinical data show attenuation of effects that are present in wild-type controls under the same administration conditions. This approach provides pharmacological evidence that the observed preclinical signals attributed to PT-141 are mediated through MC4R rather than off-target receptor engagement, a distinction that specialist investigators regard as critical for mechanistic interpretation.
The compound Bremelanotide shares the same molecular structure as research-grade PT-141 and is also the active pharmaceutical ingredient in the drug Vyleesi. However, research-grade PT-141 Bremelanotide as supplied for laboratory use is a distinct research chemical intended strictly for preclinical scientific investigation. It is not intended for, nor suitable for, human use, and researchers are reminded that all preclinical findings discussed in the melanocortin literature derive from in vitro systems or animal models. Our team supplies PT-141 exclusively for authenticated laboratory and scientific research purposes.
Specialist characterisation of research-grade PT-141 Bremelanotide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity determination, paired with mass spectrometry (MS) or liquid chromatography–mass spectrometry (LC-MS) for verified molecular weight and sequence confirmation. Expert synthesis facilities additionally provide certificates of analysis (CoA) detailing these analytical parameters. Researchers should request authenticated CoA documentation when sourcing PT-141 for preclinical work to ensure compound identity and quality standards are appropriate for their experimental requirements.
This article is for informational and educational purposes only. All compounds discussed are intended strictly for laboratory and scientific research use. Not for human consumption. Not for sale to the public.